

**Consolidated Financial Statements for the Third Quarter Ended December 31, 2017
FY2017 (April 1, 2017 - March 31, 2018)**

Company name:	Takara Bio Inc.
Stock exchange listings:	Tokyo Stock Exchange (1st section)
Code number:	4974
URL:	http://www.takara-bio.co.jp
Company representative:	Koichi Nakao, President
Contact:	Shuichiro Matsuzaki, Executive Vice President Tel. (077) 565-6970

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.

2. Amounts are rounded down to the nearest million yen.

1. Results for the three months ended December 31, 2017 (April 1, 2017 – December 31, 2018)

(1) Operating results

	(Percentages indicate changes from the same period of the previous fiscal year.)			
	Nine months ended December 31, 2017		Nine months ended December 31, 2016	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	22,646	9.7	20,645	(0.3)
Operating income	1,608	(41.0)	2,724	88.6
Ordinary income	1,762	(38.6)	2,869	69.0
Net income (loss) attributable to owners of the parent	1,068	(31.5)	1,561	154.4
Net income per share (in yen)	8.88		12.97	
Fully diluted net income per share (in yen)	-		-	
Note: Comprehensive income	881	-	(1,482)	-

(2) Financial position

	As of December 31, 2017	As of March 31, 2017
	(Millions of yen)	(Millions of yen)
Total assets	66,759	67,143
Net assets	60,315	59,985
Equity ratio (%)	90.2	89.2
Net assets per share (in yen)	500.07	497.32
(Reference) Equity	60,216	59,884

2. Dividends

	Annual dividends per share in yen		
	Year ended March 31, 2017	Year ended March 31, 2018	Year ending March 31, 2018(Forecast)
First quarter end	-	-	-
Second quarter end	-	-	-
Third quarter end	-	-	-
Year end	4.00		4.00
Annual	4.00		4.00

3. Forecast for the year ending March 31, 2018 (April 1, 2017 – March 31, 2018)

(Percentages indicated changes from the same period of the previous fiscal year.)

	Year ending March 31, 2018	
	(Millions of yen)	(%)
Net sales	33,000	12.3
Operating income	3,500	9.3
Ordinary income	3,800	6.2
Net income attributable to owners of the parent	2,000	47.9
Net income attributable to owners of the parent per share (in yen)	16.61	

Note: Correction of financial forecast from the most recent financial forecast : No

4. Others

- (1) Material changes in subsidiaries during this period
(Changes in scope of consolidations resulting from change in subsidiaries) : Yes
Newly include : 2 (Name) Rubicon Genomics, Inc., WaferGen Bio-systems, Inc.
Excluded : 2 (Name) Rubicon Genomics, Inc., WaferGen Bio-systems, Inc.
- (2) Applying of specific accounting of the consolidated quarterly financial statements : No
- (3) Changes in accounting policies, changes in accounting estimates, and retrospective restatement
- 1) Changes based on revisions of accounting standard: No
 - 2) Changes other than ones based on revisions of accounting standard: No
 - 3) Changes in accounting estimates: No
 - 4) Restatement: No
- (4) Number of outstanding shares (common stock)
- 1) Number of outstanding shares at year end (Treasury stocks are included)

As of December 31, 2017:	120,415,600
As of March 31, 2017:	120,415,600
 - 2) Number of treasury stocks at year end

As of December 31, 2017:	-
As of March 31, 2017:	-
 - 3) Average number of outstanding shares

As of December 31, 2017:	120,415,600
As of March 31, 2017:	120,415,600